Funded Startups in Naarden
Naarden’s most recent disclosed rounds skew heavily toward one biotech outlier: New Amsterdam Pharma’s $235M (2022-11-23) dwarfs the next-largest disclosed…
Naarden’s most recent disclosed rounds skew heavily toward one biotech outlier: New Amsterdam Pharma’s $235M (2022-11-23) dwarfs the next-largest disclosed amount, NorthSea Therapeutics’ $80M (2021-12-17), with the remaining disclosed rounds clustered far lower ($23M on 2025-12-10 for Founteyn; $13M on 2024-07-11 for Medal; and a $600K seed for Desty Travel on 2021-01-05). The dataset is also stage- and classification-mixed: 2 of 6 entries are “Series Unknown” (Medal, 2024-07-11 $13M; and CloudBilling, 2023-05-05 undisclosed), while 1 each shows Series A (Founteyn $23M, 2025-12-10), Series C (NorthSea Therapeutics $80M, 2021-12-17), and Seed (Desty Travel $600K, 2021-01-05).
Temporally, the six rounds span from 2021-01-05 through 2025-12-10, with two notable late-date entries (Founteyn in 2025 and Medal in 2024) separated from the highest-money biotechnology releases in 2021–2022 (NorthSea Therapeutics and New Amsterdam Pharma). Sector-wise, biotechnology appears 2 of 6 times, while the other categories are singletons (Administrative Services, Content and Publishing, Software, Other).
Most recent rounds
6 shownRelated listings
Frequently asked
What stands out as the largest disclosed round in Naarden, and how big is the gap versus the rest?
New Amsterdam Pharma’s $235M (2022-11-23) is the only disclosed round above $100M in this list and it dwarfs the next-largest disclosed amount at $80M for NorthSea Therapeutics (2021-12-17). The remaining disclosed rounds are far lower, including $23M (Founteyn, 2025-12-10), $13M (Medal, 2024-07-11), and $600K (Desty Travel, 2021-01-05).
Are there clusters in the timeline of these most recent Naarden rounds?
Within the 6 rows, the most recent edge is 2025-12-10 (Founteyn $23M), while earlier activity concentrates in 2021–2022 for the larger checks: NorthSea Therapeutics ($80M, 2021-12-17) and New Amsterdam Pharma ($235M, 2022-11-23). The remaining midpack disclosed round sits in 2024-07-11 (Medal $13M), with CloudBilling in 2023-05-05 but with an undisclosed amount.
How dominant is “Series Unknown” or undisclosed funding classifications in this set?
Two of the six entries are labeled “Series Unknown” (Medal on 2024-07-11 for $13M, and CloudBilling on 2023-05-05 with undisclosed amount). The other four entries have specific stages: Series A (Founteyn $23M, 2025-12-10), Series C (NorthSea Therapeutics $80M, 2021-12-17), and Seed (Desty Travel $600K, 2021-01-05).
Does any sector repeat, or are most categories singletons in Naarden?
Biotechnology is the only sector to recur in this slice, appearing 2 of 6 times (New Amsterdam Pharma $235M on 2022-11-23 and NorthSea Therapeutics $80M on 2021-12-17). The other sectors each show up once: Administrative Services (Founteyn), Content and Publishing (Medal), Software (CloudBilling), and Other (Desty Travel).
Which entry is the low-end outlier, and how does it compare to the disclosed range?
Desty Travel’s $600K (Seed, 2021-01-05) is the smallest disclosed amount in the table and sits well below the next-lowest disclosed round at $13M (Medal, 2024-07-11). That makes the disclosed range in this slice span from sub-$1M to $235M, with one very large biotechnology check pulling the upper tail up.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.